BIOL · Biolase, Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.85M | $11.55M | $10.13M | - | $10.92M | $14.29M | $10.47M | - | $12.01M | $12.23M |
| Cost of Revenue | $6.47M | $6.95M | $6.79M | - | $7.17M | $8.17M | $7.13M | - | $9.56M | $7.09M |
| Gross Profit | $4.38M | $4.61M | $3.34M | - | $3.75M | $6.12M | $3.34M | - | $2.44M | $5.14M |
| R&D | $917.0K | $1.07M | $1.28M | - | $1.36M | $1.44M | $1.55M | - | $1.98M | $1.65M |
| SG&A | $1.28M | $3.06M | $3.20M | - | $2.68M | $2.36M | $2.46M | - | $3.11M | $3.14M |
| Total Operating Expenses | $5.08M | $7.83M | $7.86M | - | $7.44M | $9.99M | $8.63M | - | $10.10M | $10.20M |
| D&A | $600.0K | $700.0K | $660.0K | - | $600.0K | $1.40M | $149.0K | - | $100.0K | $100.0K |
| Operating Income | ($695.0K) | ($3.22M) | ($4.53M) | - | ($3.70M) | ($3.87M) | ($5.29M) | - | ($7.65M) | ($5.05M) |
| Interest Expense | $600.0K | $600.0K | $600.0K | - | $600.0K | $600.0K | $600.0K | - | $400.0K | $400.0K |
| Income Tax | $12.0K | $20.0K | $19.0K | - | $15.0K | $31.0K | $1.0K | - | ($17.0K) | $23.0K |
| Net Income | ($1.43M) | ($2.80M) | ($6.49M) | $500.0K | ($4.59M) | ($4.87M) | ($5.85M) | - | ($8.39M) | ($5.61M) |
| EPS - Basic | ($0.04) | ($0.08) | ($0.36) | - | ($3.89) | ($8.93) | ($0.18) | - | ($1.10) | ($0.91) |
| EPS - Diluted | ($0.04) | ($0.08) | ($0.36) | - | ($3.89) | ($8.93) | ($0.81) | - | ($1.10) | ($0.91) |
Balance Sheet
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.44M | $5.27M | $6.39M | $6.57M | $7.81M | $6.93M | $6.53M | $4.18M | $9.96M | $19.55M |
| Accounts Receivable | $3.53M | $4.84M | $5.69M | $5.48M | $4.39M | $5.72M | $5.16M | $5.84M | $4.85M | $6.08M |
| Inventory | $9.87M | $10.90M | $11.27M | $11.43M | $13.82M | $13.33M | $17.77M | $15.88M | $16.43M | $16.57M |
| Accounts Payable | $3.00M | $5.49M | $4.92M | $6.07M | $7.18M | $6.31M | $7.54M | $5.79M | $4.97M | $4.96M |
| Current Assets | $19.43M | $22.09M | $25.00M | $24.86M | $27.78M | $28.15M | $31.96M | $28.96M | $33.88M | $44.27M |
| Total Assets | $27.24M | $30.64M | $34.35M | $35.10M | $38.74M | $39.63M | $41.94M | $38.19M | $42.87M | $50.85M |
| Current Liabilities | $30.86M | $31.18M | $21.43M | $19.66M | $19.78M | $18.38M | $19.00M | $17.81M | $13.76M | $13.95M |
| Long-term Debt | $0 | $150.0K | $11.21M | $11.78M | $11.31M | $11.90M | $12.50M | $13.09M | $12.79M | $12.73M |
| Total Liabilities | $32.12M | $32.77M | $34.08M | $33.15M | $32.86M | $32.29M | $33.79M | $33.30M | $29.01M | $29.24M |
| Stockholders' Equity | ($5.23M) | ($4.33M) | ($1.93M) | ($247.0K) | $332.0K | $6.62M | $8.16M | $4.89M | $13.86M | $21.61M |
| Retained Earnings | ($327.51M) | ($326.08M) | ($323.29M) | ($316.80M) | ($311.47M) | ($306.88M) | ($302.02M) | ($296.17M) | ($286.31M) | ($277.92M) |
Cash Flow
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($5.94M) | - | - | - | ($5.66M) | - | - | - |
| Investing Cash Flow | - | - | $197.0K | - | - | - | ($587.0K) | - | - | - |
| Financing Cash Flow | - | - | $5.65M | - | - | - | $8.52M | - | - | - |
| CapEx | - | - | $0 | - | - | - | $587.0K | - | - | - |
| Free Cash Flow | - | - | ($5.94M) | - | - | - | ($6.25M) | - | - | - |
Ratios
| Metric | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 40.4% | 39.9% | 32.9% | - | 34.3% | 42.8% | 31.9% | - | 20.4% | 42.0% |
| Operating margin | -6.4% | -27.9% | -44.7% | - | -33.9% | -27.1% | -50.5% | - | -63.7% | -41.3% |
| EBITDA margin | -0.9% | -21.8% | -38.2% | - | -28.4% | -17.3% | -49.1% | - | -62.9% | -40.5% |
| Net margin | -13.2% | -24.2% | -64.0% | - | -42.0% | -34.1% | -55.9% | - | -69.8% | -45.9% |
| Free cash flow margin | - | - | -58.6% | - | - | - | -59.7% | - | - | - |
| FCF / Net income | - | - | 0.92 | - | - | - | 1.07 | - | - | - |
| R&D / Revenue | 8.5% | 9.3% | 12.7% | - | 12.5% | 10.1% | 14.8% | - | 16.5% | 13.5% |
| SG&A / Revenue | 11.8% | 26.5% | 31.5% | - | 24.5% | 16.5% | 23.5% | - | 25.9% | 25.7% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -5.2% | -9.1% | -18.9% | 1.4% | -11.8% | -12.3% | -13.9% | - | -19.6% | -11.0% |
| Return on equity | 27.3% | 64.6% | 335.3% | -202.4% | -1382.2% | -73.5% | -71.7% | - | -60.5% | -26.0% |
| Return on invested capital | - | - | -38.6% | - | -25.1% | -16.5% | -20.2% | - | -22.7% | -11.6% |
| Liquidity | ||||||||||
| Current ratio | 0.63 | 0.71 | 1.17 | 1.26 | 1.40 | 1.53 | 1.68 | 1.63 | 2.46 | 3.17 |
| Quick ratio | 0.31 | 0.36 | 0.64 | 0.68 | 0.71 | 0.81 | 0.75 | 0.73 | 1.27 | 1.99 |
| Cash ratio | 0.11 | 0.17 | 0.30 | 0.33 | 0.39 | 0.38 | 0.34 | 0.23 | 0.72 | 1.40 |
| Leverage | ||||||||||
| Debt / Equity | 0.00 | -0.03 | -5.79 | -47.70 | 34.06 | 1.80 | 1.53 | 2.68 | 0.92 | 0.59 |
| Debt / Assets | 0.00 | 0.00 | 0.33 | 0.34 | 0.29 | 0.30 | 0.30 | 0.34 | 0.30 | 0.25 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -1.2x | -5.4x | -7.5x | - | -6.2x | -6.5x | -8.8x | - | -19.1x | -12.6x |
| Equity multiplier | -5.21 | -7.08 | -17.76 | -142.11 | 116.70 | 5.99 | 5.14 | 7.81 | 3.09 | 2.35 |
| Liabilities / Assets | 1.18 | 1.07 | 0.99 | 0.94 | 0.85 | 0.81 | 0.81 | 0.87 | 0.68 | 0.57 |
| Efficiency | ||||||||||
| Asset turnover | 0.40 | 0.38 | 0.29 | - | 0.28 | 0.36 | 0.25 | - | 0.28 | 0.24 |
| Inventory turnover | 0.66 | 0.64 | 0.60 | - | 0.52 | 0.61 | 0.40 | - | 0.58 | 0.43 |
| Days sales outstanding | 119d | 153d | 205d | - | 147d | 146d | 180d | - | 147d | 181d |
| Days inventory outstanding | 557d | 573d | 606d | - | 703d | 596d | 910d | - | 627d | 853d |
| Days payable outstanding | 169d | 289d | 264d | - | 365d | 282d | 386d | - | 190d | 255d |
| Cash conversion cycle | 506d | 437d | 546d | - | 485d | 460d | 704d | - | 584d | 779d |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -0.7% | -19.1% | -3.2% | - | -9.1% | 16.8% | 3.0% | - | 26.0% | 34.0% |
| Revenue CAGR (3y) | 4.4% | 8.2% | 7.7% | - | 18.6% | 69.4% | 29.8% | - | 11.6% | 12.3% |
| Revenue CAGR (5y) | 4.6% | 6.0% | -0.4% | - | -0.0% | 3.3% | -0.8% | - | 2.1% | -0.6% |
| Gross profit growth (YoY) | 17.0% | -24.7% | -0.0% | - | 53.2% | 19.0% | -29.4% | - | -49.5% | 27.2% |
| Operating income growth (YoY) | 81.2% | 16.8% | 14.5% | - | 51.7% | 23.4% | -25.8% | - | -188.0% | -54.0% |
| Net income growth (YoY) | 68.9% | 42.5% | -10.9% | - | 45.3% | 13.2% | -22.5% | - | -156.0% | -699.3% |
| EPS growth (YoY) | 99.0% | 99.1% | 55.6% | - | -253.6% | -881.3% | - | - | -5400.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | 4.9% | - | - | - | 25.0% | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | - | - | -97.6% | -69.4% | -60.4% | -80.6% | -54.3% | -35.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2023-12-31.
Product / service
$49.16M totalLaser Systems$30.04M · 61.1%
Consumable And Other$13.60M · 27.7%
Service$5.53M · 11.2%
Geographic
$49.16M totalUS$33.88M · 68.9%
Non Us$15.28M · 31.1%
Peer comparison
Same SIC group: Dental Equipment & Supplies
Comparing BIOLASE against the 5 most active filers in the same SIC group.